Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

COCP

+ Watchlist+ Portfolio

Cocrystal Pharma, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.01
52-Week Range
$0.76 – $2.03
Market Cap
$18.82M
P/E (TTM)
—
EPS (TTM)
-0.76
Dividend Yield
0.00%
Advanced Metrics
Price/Book
7.03
PEG Ratio
—
Return on Equity
-219.12%
Return on Assets
-83.56%
Gross Margin
0.00%
Operating Margin
-2645.98%
Profit Margin
0.00%
Current Ratio
1.72
Debt/Equity
0.47
Total Debt
$1.26M
Free Cash Flow
—
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$15.20M

Market Snapshot

About

Cocrystal Pharma, Inc. is a biotechnology company focused on the discovery and development of novel antiviral therapeutics. Headquartered in Bothell, Washington, the company uses proprietary structure-based drug design technologies to create first-in-class and best-in-class antiviral drugs. Cocrystal's pipeline includes antiviral programs targeting influenza, norovirus, hepatitis C virus, and coronaviruses including SARS-CoV-2. The company's technology platform enables the design of inhibitors that target viral replication mechanisms.